84348-41-4

Basic information

• Product Name: (S)-methyl 4-methylenepyrrolidine-2-carboxylate hydrochloride
• Synonyms: (S)-methyl 4-methylenepyrrolidine-2-carboxylate hydrochloride
• CAS NO: 84348-41-4
• Molecular Weight: 177.631
• Mol File: 84348-41-4.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: (S)-methyl 4-methylenepyrrolidine-2-carboxylate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-methyl 4-methylenepyrrolidine-2-carboxylate hydrochloride(84348-41-4)
• EPA Substance Registry System: (S)-methyl 4-methylenepyrrolidine-2-carboxylate hydrochloride(84348-41-4)

Safety Data

• Hazardous Substances Data: 84348-41-4(Hazardous Substances Data)

Usage

Description

(S)-methyl 4-methylenepyrrolidine-2-carboxylate hydrochloride is a chemical compound that serves as an intermediate in the synthesis of pharmaceutical compounds, particularly those used in the treatment of psychological conditions such as anti-psychotic and anti-depressant medications. It is a salt form of a carboxylic acid synthesized through a specific reaction process and requires careful handling due to potential hazards.

Uses

Used in Pharmaceutical Industry:
(S)-methyl 4-methylenepyrrolidine-2-carboxylate hydrochloride is used as a synthetic intermediate for the production of various drugs, including anti-psychotic and anti-depressant medications. Its role in the synthesis process is crucial for creating effective treatments for mental health disorders.
Used in Chemical Synthesis:
(S)-methyl 4-methylenepyrrolidine-2-carboxylate hydrochloride is also used as a building block in the chemical synthesis of other complex molecules, contributing to the development of a diverse range of pharmaceutical products. Its versatility in chemical reactions makes it a valuable component in the creation of new and innovative medications.

Upstream product

• 84348-38-9 (S)-1-(tert-butoxycarbonyl)-4-methylenepyrrolidine-2-carboxylic acid 
• 84348-39-0 (S)-1-tert-butyl 2-methyl 4-methylenepyrrolidine-1,2-dicarboxylate 
• 79-37-8 oxalyl dichloride 
• 57-50-1 Sucrose 
• 67-56-1 methanol 
• 84348-40-3 methyl 4-methylene-L-proline 

Downstream Products

• 1343476-08-3 (S)-(4,4‘-(pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((S)-2-(methoxycarbonyl)-4-methylenepyrrolidin-1-yl)methanone) 
• 945490-07-3 1-(4-benzyloxy-5-methoxy-2-nitrobenzoyl)-(2S)-4-methylenepyrrolidine-2-carboxylic acid methyl ester 
• 1430738-22-9 (S)-(2-(((tert-butyldimethylsilyl)oxy)methyl)-4-methyl-2,3-dihydro-1H-pyrrol-1-yl)(5-methoxy-2-nitro-4-((triisopropylsilyl)oxy)phenyl)methanone 

Relevant articles and documents

VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS

The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking; to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.

CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES

A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.

PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF

Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.